Correlation Between Nascent Biotech and PhaseBio Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Nascent Biotech and PhaseBio Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Nascent Biotech and PhaseBio Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Nascent Biotech and PhaseBio Pharmaceuticals, you can compare the effects of market volatilities on Nascent Biotech and PhaseBio Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Nascent Biotech with a short position of PhaseBio Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Nascent Biotech and PhaseBio Pharmaceuticals.

Diversification Opportunities for Nascent Biotech and PhaseBio Pharmaceuticals

0.15

Correlation Coefficient

Nascent Biotech  PhaseBio Pharmaceuticals

Average diversification

The 3 months correlation between Nascent and PhaseBio is 0.15. Overlapping area represents the amount of risk that can be diversified away by holding Nascent Biotech and PhaseBio Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on PhaseBio Pharmaceuticals and Nascent Biotech is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Nascent Biotech are associated (or correlated) with PhaseBio Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of PhaseBio Pharmaceuticals has no effect on the direction of Nascent Biotech i.e., Nascent Biotech and PhaseBio Pharmaceuticals go up and down completely randomly.

Pair Corralation between Nascent Biotech and PhaseBio Pharmaceuticals

Given the investment horizon of 90 days Nascent Biotech is expected to generate 121.63 times less return on investment than PhaseBio Pharmaceuticals. But when comparing it to its historical volatility, Nascent Biotech is 15.59 times less risky than PhaseBio Pharmaceuticals. It trades about 0.02 of its potential returns per unit of risk. PhaseBio Pharmaceuticals is currently generating about 0.17 of returns per unit of risk over similar time horizon. If you would invest  2.00  in PhaseBio Pharmaceuticals on September 13, 2024 and sell it today you would lose (1.97) from holding PhaseBio Pharmaceuticals or give up 98.5% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	29.09%
Values	Daily Returns

Nascent Biotech  vs.  PhaseBio Pharmaceuticals

Nascent Biotech

Risk-Adjusted Performance

7 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Nascent Biotech are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of very weak forward indicators, Nascent Biotech displayed solid returns over the last few months and may actually be approaching a breakup point.

PhaseBio Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days PhaseBio Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, PhaseBio Pharmaceuticals is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors.

Pair Trading with Nascent Biotech and PhaseBio Pharmaceuticals

The main advantage of trading using opposite Nascent Biotech and PhaseBio Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Nascent Biotech position performs unexpectedly, PhaseBio Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in PhaseBio Pharmaceuticals will offset losses from the drop in PhaseBio Pharmaceuticals' long position.

The idea behind Nascent Biotech and PhaseBio Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.